Dani Paul Bolognesi
Vorstandsvorsitzender bei B3 Bio, Inc.
Profil
Dani Paul Bolognesi is the founder of B3 Bio, Inc. (founded in 2007) where he holds the title of Chairman & Chief Executive Officer.
He is currently a Director at Senex Biotechnology, Inc. and Istari Oncology, Inc. Dr. Bolognesi has also held positions as a Director at Transgeneron Therapeutics, Inc., Duke University, and InnAVasc Medical, Inc. From 1993 to 2004, he served as the Chief Executive & Scientific Officer at Trimeris, Inc. Dr. Bolognesi obtained a doctorate degree from Duke University.
Aktive Positionen von Dani Paul Bolognesi
| Unternehmen | Position | Beginn |
|---|---|---|
| B3 Bio, Inc. | Vorstandsvorsitzender | 10.09.2009 |
Istari Oncology, Inc.
 Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Direktor/Vorstandsmitglied | 01.01.2016 |
Senex Biotechnology, Inc.
 Senex Biotechnology, Inc. BiotechnologyHealth Technology Senex Biotechnology, Inc. is a drug discovery and development company focused on oncology therapeutics. The company was founded by Igor B. Roninson and is headquartered in Columbia, SC. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Dani Paul Bolognesi
| Unternehmen | Position | Ende |
|---|---|---|
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Präsident | - |
InnAVasc Medical, Inc.
 InnAVasc Medical, Inc. Medical SpecialtiesHealth Technology InnAVasc Medical, Inc. designs and develops products for vascular access for hemodialysis. Its technology vascular access graft is designed to create one contiguous flow lumen without transition points. The company is headquartered in Durham, NC. | Direktor/Vorstandsmitglied | - |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | Direktor/Vorstandsmitglied | - |
Transgeneron Therapeutics, Inc.
 Transgeneron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transgeneron Therapeutics, Inc. researches and develops therapies to treat diseases. It develops therapeutic medicine that promotes tissue regeneration by reprogramming healthy tissue. This therapeutic reprogramming causes cells to 'trans-differentiate' into cells that can replace diseased or degenerated organs. The company was founded in April 2007 and is located in Gainesville, FL | Direktor/Vorstandsmitglied | - |
Ausbildung von Dani Paul Bolognesi
| Duke University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
Transgeneron Therapeutics, Inc.
Transgeneron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Transgeneron Therapeutics, Inc. researches and develops therapies to treat diseases. It develops therapeutic medicine that promotes tissue regeneration by reprogramming healthy tissue. This therapeutic reprogramming causes cells to 'trans-differentiate' into cells that can replace diseased or degenerated organs. The company was founded in April 2007 and is located in Gainesville, FL | Health Technology |
Senex Biotechnology, Inc.
Senex Biotechnology, Inc. BiotechnologyHealth Technology Senex Biotechnology, Inc. is a drug discovery and development company focused on oncology therapeutics. The company was founded by Igor B. Roninson and is headquartered in Columbia, SC. | Health Technology |
| B3 Bio, Inc. | |
InnAVasc Medical, Inc.
InnAVasc Medical, Inc. Medical SpecialtiesHealth Technology InnAVasc Medical, Inc. designs and develops products for vascular access for hemodialysis. Its technology vascular access graft is designed to create one contiguous flow lumen without transition points. The company is headquartered in Durham, NC. | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Health Technology |
